Aβ Classification Predicts Outcomes in Pediatric Ketosis- Prone Diabetes
* You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
In this presentation, Dr. Mustafa Tosur discusses the heterogeneity of pediatric ketosis-prone diabetes (KPD) and the Aβ framework for the classification of diabetes. Furthermore, he describes recent studies of Aβ-defined pediatric KPD subgroups and their the long-term metabolic and clinical outcomes.
This Endocrine Grand Rounds session took place on Friday, January 16, 2026 at 12:15 p.m.
Activity Information
How to Claim Credit
You may claim credit after watching this activity.
You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
Needs Statement
To ensure accurate and effective patient care, healthcare providers in endocrinology require enhanced knowledge of core endocrine conditions, including the latest diagnostic and therapeutic approaches. There is a need to strengthen competence in applying evidence-based medicine and clinical guidelines, while also promoting high-value care and performance excellence across all disciplines within endocrinology. Additionally, providers must understand the scientific rigor behind guideline development and explore novel models of multidisciplinary care that foster collaboration and improve patient outcomes. This series aims to support these needs by offering regular updates on advances in basic science and clinical research, emerging treatment modalities, and evolving management strategies for endocrine disorders. By inviting expert speakers, the series delivers authoritative insights and practical strategies for improving clinical outcomes.
Educational Objectives
At the conclusion of the activity, the participants should be able to:
- Define the heterogeneity of pediatric ketosis-prone diabetes (KPD) using the Aβ classification framework based on islet autoimmunity and β-cell functional reserve.
- Compare long-term metabolic and clinical outcomes across Aβ-defined pediatric KPD subgroups and identify early predictors of these outcomes.
- Apply Aβ classification to individualized clinical management in youth with KPD.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
- Nurses
- Other Health Professionals
Specialties
- Endocrinology, Diabetes and Metabolism
- Pediatrics
Interest Groups
- Hospital Medicine
Activity Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.
Educational Methods
- Lectures
- Case Presentations
- Literature Review
- Panel Discussion
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Directors
-
-
Mark A. Herman, M.D.
Associate Professor of Endocrinology, Diabetes, and Metabolism; E.L. Wagner, MD Chair of Internal Medicine
Baylor College of Medicine
Term of Approval
January 1, 2026 through January 31, 2028. Original release date: January 1, 2026.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Mustafa Tosur, M.D.
Associate Professor of Pediatrics, Division of Diabetes and Endocrinology
Baylor College of Medicine; Texas Children's Hospital
Disclosure:
Nothing to disclose.
Activity Directors
-
-
Mark A. Herman, M.D.
Associate Professor of Endocrinology, Diabetes, and Metabolism; E.L. Wagner, MD Chair of Internal Medicine
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
-
Jordana Faruqi, M.D., M.P.H.
Endocrinology Fellow
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Sean Hartig, Ph.D.
Associate Professor, Division of Endocrinology, Diabetes and Metabolism
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Mark A. Herman, M.D.
Associate Professor of Endocrinology, Diabetes, and Metabolism; E.L. Wagner, MD Chair of Internal Medicine
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Jennifer Kaplan, M.D.
Endocrinology Fellow
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Health Topics
Presenter: